Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi（新）
GUSD（纯图）
Rewards

Corelon Tissue's Cell Therapy Fails, HLB's FDA Approval Delayed Amid K-Biotech Selloff

GateNews
Stocks
HLB-6.90%

According to Korean media reports, South Korea's biotech sector faced significant headwinds today as Corelon Tissue announced clinical failure in its osteoarthritis cell gene therapy candidate (TG-), while HLB experienced further delays in its U.S. FDA approval process.

Unlike previous market downturns, individual biotech stock setbacks are not cascading across the entire sector, creating an opportunity for investors to differentiate quality companies from weaker players.

View Source
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

3h ago
Korean NewCo IPOs Stumble; 17 of 20 Below Offer Price on July 22
8h ago
Korean Retail Investors Flock to 3x Leverage ETFs as Regulator Targets Single-Stock Products
07-21 06:38
Domestic Funds Disguised as Foreign Investors Dodge South Korea IPO Commitments
07-21 03:02
Samchundang Pharma Plunges 27%, Kolon TissuGene Falls 29% on July 21 Over FDA Feedback and Failed Clinical Trial
07-20 12:22
South Korean Retail Investors Lose Heavily as Samsung, SK Hynix Leveraged ETFs Plunge 70% After Semiconductor Reversal
In-Depth Analysis

Alteogen Postpones KOSPI Transfer, Remains on KOSDAQ

Lucas Bennett2h ago

Kolon Stocks Crash 28% After TG-C Phase 3 Clinical Trial Fails

Lucas Bennett4h ago

HLB Genex Executives Purchase Shares Amid Stock Decline

Lucas Bennett5h ago
Comment
0/400
No comments